Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: HspE7 (Stressgen).

Paulo Cesar Maciag1, Yvonne Paterson

  • 1University of Pennsylvania, Department of Microbiology, 36th St and Hamilton Walk, Philadelphia, PA 19104-6076, USA.

Current Opinion in Molecular Therapeutics
|June 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined radiation and <i>Listeria</i> immunotherapy induces cytotoxic immunity that correlates with improved outcome in dogs with osteosarcoma.

Molecular therapy. Oncology·2026
Same author

Association Between Human Leukocyte Antigen Polymorphism and Human Papillomavirus Infection in Brazilian Women.

Sexually transmitted diseases·2022
Same author

Purification of Immunoglobulin G Fraction from Antiserum, Ascites Fluid, or Hybridoma Supernatant: Immunology.

Current protocols in molecular biology·2021
Same author

Production of Polyclonal Antisera in Rabbits: Immunology.

Current protocols in molecular biology·2021
Same author

Production of Antipeptide Antibodies: Immunology.

Current protocols in molecular biology·2021
Same author

Selection of an Immunogenic Peptide: Immunology.

Current protocols in molecular biology·2021
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Stressgen is developing HspE7, a novel fusion protein therapy targeting human papillomavirus (HPV) infections. This innovative treatment, combining HPV E7 antigen and heat shock protein Hsp65, is advancing through phase III clinical trials.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Human papillomavirus (HPV) infections are a major cause of various cancers.
  • Current therapeutic options for HPV-associated conditions have limitations.
  • There is a need for novel treatment strategies to combat HPV infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of HspE7 as a potential therapy for HPV-associated conditions.
  • To assess the immunogenicity of the HspE7 fusion protein.
  • To advance the development of HspE7 through clinical trials.

Main Methods:

  • Development of HspE7, a recombinant fusion protein linking HPV E7 antigen and Mycobacterium bovis Hsp65.
  • Preclinical studies to assess HspE7's biological activity and safety profile.

Related Experiment Videos

  • Phase III clinical trials to evaluate therapeutic efficacy in patients with HPV infections.

    • Main Results:

    • HspE7 demonstrates potential as a therapeutic agent against HPV.
    • The fusion protein elicits an immune response against HPV antigens.
    • Ongoing phase III trials are crucial for confirming clinical benefit.

    Conclusions:

    • HspE7 represents a promising novel immunotherapy for HPV-related diseases.
    • Further clinical investigation is warranted to establish HspE7's role in HPV treatment.
    • Successful completion of phase III trials could lead to a new therapeutic option for HPV infections.